Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Details for Australian Patent Application No. 2002231244 (hide)

International Classifications

Event Publications

23 January 2003 Application Open to Public Inspection

Published as AU-B-2002231244

16 December 2004 Assignment before Grant

Salus Pharma, Inc. The application has been assigned to Corus Pharma, Inc.

29 June 2006 Application Accepted

Published as AU-B-2002231244

26 October 2006 Standard Patent Sealed

13 November 2008 Assignment Registered

Corus Pharma, Inc. The patent has been assigned to Gilead Sciences, Inc.

27 May 2010 Extension of Term of Standard Patents

Gilead Sciences, Inc. The earliest first regulatory approval date provided by the patentee 04 Feb 2010 For the goods CAYSTON aztreonam

3 June 2010 Extension of Term of Standard Patents

Gilead Sciences, Inc. The earliest first regulatory approval date provided by the patentee 04 Feb 2010 For the goods CAYSTON aztreonam Address for service in Australia: Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

25 November 2010 Extension granted

Gilead Sciences, Inc. The earliest first regulatory approval date provided by the patentee 04 Feb 2010 For the goods CAYSTON aztreonam Extensions of Term of Standard Patents Extension of Term of a Standard Patent relating to Pharmaceutical Substances Extensions granted Extension of Term of patent pursuant to Section 77 expires on 04 Feb 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.